Eugene B. Cone, MD

The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.

Experts on non–muscle invasive bladder cancer discuss promising developments in the overall treatment landscape, highlighting potentially practice-changing clinical research.

Bladder cancer specialists discuss their strategies for monitoring patients with BCG-unresponsive non–muscle invasive bladder cancer.

A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

Bladder cancer experts discuss quality of life and progression considerations and their impact on treatment decisions for patients with BCG-unresponsive NMIBC.

Jason Hafron, MD, CMO, provides an overview of the QUILT trial investigating N-803 in patients with BCG-unresponsive high-grade non–muscle invasive bladder cancer.

The panel reviews data from the SunRISe-1 trial investigating TAR-200 and offers its impressions on the efficacy and safety findings.

Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.

A panel of experts on non–muscle invasive bladder cancer (NMIBC) discuss challenges associated with BCG shortages and the impact on treatment options and patients’ quality of life.